CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $68.06 Average Target Price from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have received an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $68.0556.

Several equities analysts have recently weighed in on CRSP shares. UBS Group set a $80.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 12th. Morgan Stanley set a $60.00 price objective on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Tuesday, August 25th. Finally, HC Wainwright reissued a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, August 31st.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its stake in shares of CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth $26,000. Rothschild Investment LLC raised its holdings in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after acquiring an additional 502 shares during the period. Larson Financial Group LLC boosted its position in shares of CRISPR Therapeutics by 263.0% during the 4th quarter. Larson Financial Group LLC now owns 882 shares of the company’s stock valued at $46,000 after acquiring an additional 639 shares during the last quarter. Finally, Ameritas Advisory Services LLC acquired a new position in shares of CRISPR Therapeutics during the 2nd quarter valued at about $56,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 0.7%

NASDAQ CRSP opened at $52.21 on Monday. The business has a fifty day moving average price of $52.99 and a 200 day moving average price of $52.82. CRISPR Therapeutics has a one year low of $44.12 and a one year high of $78.48. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The company has a market cap of $5.05 billion, a P/E ratio of -10.97 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million during the quarter. Research analysts anticipate that CRISPR Therapeutics will post -4.47 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.